Anti-EGFR therapy
RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer
... that anti-EGFR therapy should perhaps not be totally discarded when tumors have RAS ...for therapy testing ...factors, EGFR inhibitors, and genetic deletion of Rasgrp1, since Rasgrp1 ...
17
Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer
... targeted therapy, overall survival (OS) of metastatic colorectal cancer (mCRC) patients has been significantly increased over the past ...targeted therapy, we collected randomized controlled trials which ...
7
<p>Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study</p>
... that EGFR signaling plays a vital role in NPC pathogenesis. 7 EGFR is reportedly overexpressed in 80 – 89% of NPC patients, which may be responsible for treatment resistance and poor ...rst EGFR ...
10
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
... 7. Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Pretet JL, Bieche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier- ...
7
Positive feedback between oncogenic KRAS and HIF-1α confers drug resistance in colorectal cancer
... to anti-epidermal growth factor receptor (EGFR) therapy, and poor survival ...to EGFR inhibitors in colorectal cancer cells harboring KRAS G12V mutation is associated with ...an EGFR ...
9
Original Article Temozolomide and targeted therapy against epidermal growth factor receptor in glioma
... TMZ therapy and by ...TMZ therapy and by 1 in comparison to anti-EGFR therapy after the seventh ...single, anti-EGFR therapy at the eleventh day of the ...TMZ ...
13
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
... We present a few putative mechanisms underlying the efficacy we observed with dual anti-EGFR and anti-VEGF inhibition in CRC patients. First, unlike earlier studies (17– 20, 22), we selected only ...
11
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
... on anti-EGFR therapy prior to collection of ...this anti-EGFR therapy refractory cohort was detected on cfDNA in 12 ...in anti-EGFR naïve tumor tissue-based ...
5
KRAS and BRAF mutational status in colon cancer from Albanian patients
... BRAF should also be tested together with KRAS to select the patients who are most likely to benefit from the anti- EGFR therapy [19,32,33]. Our objective was the determine the frequency of most ...
7
Targeting metastatic colorectal cancer – present and emerging treatment options
... for anti-EGFR therapy selection; furthermore, biomarkers for the anti-VEGF agents are ...and therapy will not only minimize ineffective treatments for mCRC patients, but also improve ...
8
Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer
... to anti-EGFR treatment therapy in a sim- ilar manner as patients with KRAS wild type ...from anti-EGFR ...biological therapy (p = ...
8
Molecular analysis and clinicopathologic features of advanced colorectal cancer in Algerian patients
... from anti- EGFR therapy associated with chemotherapy [15, ...the anti-EGFR therapies have shown to be effective in patients with ...
8
Lapatinib capecitabine versus capecitabine alone as radiosensitizers in RAS wild type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial
... both EGFR and ...of anti-EGFR therapy in RAS wild-type colorectal cancer [19 – 23, 39] and the theoretical advan- tage of anti-EGFR treatment during radiotherapy [26, 27] ...
13
Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream
... Significant advances have been made in the development of molecular biomarkers for the treatment of mCRC. Unlike BRAF, mutations in RAS genes (KRAS and NRAS) do not have a definite prognostic significance in mCRC. ...
14
Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
... cationic lipid and siRNA. The prepared immunonanoparticles were then loaded on 1% agarose gels (Figure 2). According to gel retardation analysis, encapsulation of siRNA into the anti-EGFR immunoliposomes ...
14
Glioblastoma without Remarkable Contrast Enhancement on Magnetic Resonance Imaging
... ((e), anti-p53 stain- ing, original magnification ×100), while none of the tumor cells were immunoreactive for EGFR ((f), anti-EGFR stain- ing, original magnification ×100) or IDH1 ((g), ...
7
Postoperative survival of EGFR TKI targeted therapy in non small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
... common EGFR mutations in NSCLC. These mutations represented 85 to 90% of EGFR mutations [12, ...population, EGFR mutations were identified in ...an EGFR exon 19 deletion and 372 patients with ...
8
Muc1 oncogene: clinical prospects in human breast cancer
... In different carcinoma, MUC1 is overexpressed with aberrant glycosylation. These differences observed between normal and aberrantly glycosylated MUC1 encouraged the research on ability to recognize humoral MUC1 epitopes ...
6
RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src
... ranK, egFr, aKT, erK, and phosphorylation levels were analyzed by Western ...of egFr, aKT, and erK and phosphorylation levels were analyzed by Western ...
11
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
... and anti-EGFR-Ab-treatment should only be administered for tumors that are wild- type (WT) at these loci (Allegra et ...influence anti-EGFR-Ab ...
56